Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Reports of “Ozempic parties” followed, and, as the drug’s popularity surged, supply became a drag in various countries.

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

Semaglutide remains on the agency’s drug shortage list, but all FDA-approved forms of the drug are no longer labeled ...

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in overweight patients with cardiovascular disease.

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...